| Dr Molly C O'brien-horn, PT, DPT, CLT | |
|
901 W Main St, Freehold, NJ 07728-2537 | |
| (732) 294-2700 | |
| Not Available |
| Full Name | Dr Molly C O'brien-horn |
|---|---|
| Gender | Female |
| Speciality | Physical Medicine & Rehabilitation |
| Location | 901 W Main St, Freehold, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891272100 | NPI | - | NPPES |
| PT023787 | Other | PA | PENNSYLVANIA PT LICENSE NUMBER |
| 40QA01583200 | Other | NJ | NEW JERSEY PT LICENSE NUMBER |
| PT294967 | Other | CA | CALIFORNIA PT LICENSE NUMBER |
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
A long-term study spanning five years and including more than 3,000 nationally-representative older US adults has found that a natural decline of the five classical senses (vision, hearing, taste, smell and touch) can predict a number of poor health outcomes, including greater risk of death.
Despite facing challenges such as limited access to personal protective equipment (PPE) following the COVID-19 outbreak, radiation oncology clinics quickly implemented safety and process enhancements that allowed them to continue caring for cancer patients, according to a new national survey from the American Society for Radiation Oncology (ASTRO).
Sen. Max Baucus' pursuit of a bipartisan health care reform bill is being met with increasing skepticism from his own party.
Certain patients with inflammatory bowel disease (IBD) may have an increased risk of skin cancer, which is intensified by the use of immunosuppressant medications , according to two new studies in Gastroenterology, the official journal of the American Gastroenterological Association. Immunosuppressants are commonly used in the treatment of IBD.
Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Molly C O'brien-horn, PT, DPT, CLT 1411 Northumberland Way, Monmouth Junction, NJ 08852-2371 Ph: (609) 457-1660 | Dr Molly C O'brien-horn, PT, DPT, CLT 901 W Main St, Freehold, NJ 07728-2537 Ph: (732) 294-2700 |
News Archive
A long-term study spanning five years and including more than 3,000 nationally-representative older US adults has found that a natural decline of the five classical senses (vision, hearing, taste, smell and touch) can predict a number of poor health outcomes, including greater risk of death.
Despite facing challenges such as limited access to personal protective equipment (PPE) following the COVID-19 outbreak, radiation oncology clinics quickly implemented safety and process enhancements that allowed them to continue caring for cancer patients, according to a new national survey from the American Society for Radiation Oncology (ASTRO).
Sen. Max Baucus' pursuit of a bipartisan health care reform bill is being met with increasing skepticism from his own party.
Certain patients with inflammatory bowel disease (IBD) may have an increased risk of skin cancer, which is intensified by the use of immunosuppressant medications , according to two new studies in Gastroenterology, the official journal of the American Gastroenterological Association. Immunosuppressants are commonly used in the treatment of IBD.
Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A.
› Verified 2 days ago
Dr. Michael Viray Lacap, M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 20 Thoreau Dr, Poets Square, Freehold, NJ 07728 Phone: 732-303-1425 | |
Dr. Anatoly Shnayder, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 515 Iron Bridge Rd, Freehold, NJ 07728 Phone: 732-205-1707 | |
Jennifer Csontos, RD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 77 Schanck Rd # 55, Suite B-11, Freehold, NJ 07728 Phone: 732-677-3733 | |
Andrew Goelz, DPT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3 Paragon Way Ste 250, Freehold, NJ 07728 Phone: 732-431-2883 Fax: 732-431-2883 | |
James E Engelman, D.O. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 901 W Main St, Freehold, NJ 07728 Phone: 732-431-5024 Fax: 732-431-2561 | |
Shawn Soloveychik, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 901 W Main St, Freehold, NJ 07728 Phone: 732-431-2000 |